3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Gallbladder Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts